In a prostate cancer study, monensin was found to bind to the DNA-binding domain (DBD) of FOXM1, reducing its interaction with downstream target genes such as PLK1 and CDC25B, thereby exerting an anti-cancer effect (101). This evidence concerns the gene FOXM1 and prostate cancer.